Galapagos to acquire CellPoint and AboundBio to accelerate access to next-generation cell therapies.

Mechelen, Belgium, Leiden, the Netherlands, Pittsburgh, Pennsylvania, United States; 21 June 2022, 22.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG), CellPoint and AboundBio today announced that both companies have entered into definitive agreements with Galapagos, propelling Galapagos into next-generation cell therapy while significantly broadening its portfolio and capabilities. Consulter la publication complèt ici